Welcome to our dedicated page for Context Therapeutics news (Ticker: CNTX), a resource for investors and traders seeking the latest updates and insights on Context Therapeutics stock.
Context Therapeutics Inc. (CNTX) is a clinical-stage biopharmaceutical company focused on T cell engaging (TCE) bispecific antibodies for solid tumors. The CNTX news feed on Stock Titan aggregates company press releases and related coverage so readers can follow how its pipeline and corporate activities evolve over time.
According to recent announcements, Context is advancing three key programs: CTIM-76, a Claudin 6 x CD3 TCE in a Phase 1 dose-escalation trial for CLDN6-positive ovarian, endometrial, and testicular cancers; CT-95, a Mesothelin x CD3 TCE in a Phase 1 study for mesothelin-expressing solid tumors such as pancreatic, non-small cell lung, ovarian, mesothelioma, and colorectal cancers; and CT-202, a Nectin-4 x CD3 TCE in preclinical development with pH-dependent activity designed for the tumor microenvironment. News items often highlight clinical enrollment updates, early safety and anti-tumor activity signals, and preclinical data presented at major oncology meetings.
Investors and followers of CNTX can also see updates on quarterly operating and financial results, at-the-market equity program changes, Nasdaq listing compliance notices and resolutions, and organizational developments such as inducement stock option grants and senior leadership appointments. The company regularly reports participation in scientific and investor conferences, including ASCO, AACR, SITC, and healthcare investment forums, which can signal upcoming data disclosures or corporate visibility efforts.
Use this page to review Context Therapeutics’ latest clinical, financial, and corporate news in one place. For those tracking immuno-oncology and T cell engager developments in solid tumors, the CNTX news stream provides a consolidated view of the company’s reported progress and key milestones.
Context Therapeutics Inc. (Nasdaq: CNTX) announced promising data from the ONAWA trial at the 2021 San Antonio Breast Cancer Symposium. The trial evaluated onapristone extended release (ONA-XR) in postmenopausal women with PR+ early breast cancer. Results indicated a significant decrease in tumor cell proliferation, especially in tumors with high PR expression. Additionally, two other trials on ONA-XR for metastatic breast cancer were presented. The data suggest ONA-XR's potential as a therapeutic option for hormone-driven cancers, with further evaluations planned in 2022.
Context Therapeutics (Nasdaq: CNTX) has successfully closed a private placement, raising approximately $31.25 million by selling 5,000,000 shares of common stock along with 5,000,000 warrants. Each share and warrant were offered at a combined price of $6.25, with a warrant exercise price also set at $6.25 and a term of five and a half years. The proceeds will enhance the company’s oncology treatment initiatives, particularly its lead candidate, ONA-XR, aimed at tackling hormone-driven breast and gynecological cancers.
Context Therapeutics Inc. (Nasdaq: CNTX) announced a $31.25 million private placement and raised $28.75 million from its IPO. The company focuses on developing treatments for breast and gynecological cancers and has initiated patient dosing in a Phase 2 clinical trial targeting ER+, PR+, HER2- metastatic breast cancer. Recent financial results report a net loss of $1.4 million for Q3 2021 and increased R&D and G&A expenses. Context expects its financial resources will sustain operations until 2024, with ongoing clinical trials for its lead candidate, ONA-XR.
Context Therapeutics (Nasdaq: CNTX) announced a private placement, securing approximately $31.25 million from the sale of 5,000,000 shares of common stock and warrants to purchase an additional 5,000,000 shares. Each share and accompanying warrant are priced at $6.25. The placement is set to close on December 6, 2021, subject to usual conditions. The shares and warrants will not be registered under the Securities Act and may not be sold in the U.S. without registration or an exemption. Context is focused on innovating treatments for breast and gynecological cancers.
Context Therapeutics (Nasdaq: CNTX) announced that clinical data for ONA-XR will be presented at the 2021 San Antonio Breast Cancer Symposium from December 7-10, 2021. The presentations will include primary results from the ONAWA trial, focusing on early-stage breast cancer, as well as updates from ongoing trials in metastatic breast cancer. ONA-XR targets progesterone receptor-positive cancers and is currently undergoing multiple Phase 1b and Phase 2 trials. The company aims to highlight the drug's potential impact on treatment outcomes.
Context Therapeutics has appointed Jennifer Minai-Azary as Chief Financial Officer and Alex Levit as Chief Legal Officer, as announced on November 1, 2021. This leadership change follows the company's recent debut on Nasdaq and aims to strengthen its position in developing treatments for hormone-driven women's cancers. Minai-Azary, with over 20 years of experience, previously served as CFO at Millendo Therapeutics, while Levit brings nearly two decades of legal expertise in the biopharma sector. Both executives are expected to drive the company's strategic growth and clinical milestones.
Context Therapeutics has initiated its Phase 2 trial, the SMILE Study, evaluating ONA-XR (onapristone extended release) in combination with fulvestrant for patients suffering from ER-positive, PR-positive, HER2-negative metastatic breast cancer who have previously progressed on endocrine therapies and CDK4/6 inhibitors. The trial aims to enroll up to 39 patients, focusing on overall response rate and other key metrics. The study is designed to explore ONA-XR's effectiveness in overcoming treatment resistance in this patient population.
Context Therapeutics (Nasdaq: CNTX) has successfully closed its initial public offering of 5,750,000 shares at $5.00 each, raising $28.75 million in gross proceeds. The offering included a full exercise of the underwriter's option to purchase an additional 750,000 shares. ThinkEquity served as the sole book-running manager. The registration statement became effective on October 19, 2021, with offerings made by means of a prospectus. Context is focused on developing treatments for hormone-driven breast and gynecological cancers.
Context Therapeutics Inc. (Nasdaq: CNTX) has priced its initial public offering (IPO) at $5.00 per share, aiming to raise $25.0 million through the sale of 5,000,000 shares. The underwriter has a 45-day option for an additional 750,000 shares. Trading is set to begin on the Nasdaq Capital Market on October 20, 2021, with the offering expected to close on October 22, 2021, pending customary conditions. The company focuses on advanced treatments for hormone-driven breast and gynecological cancers, with a robust clinical program for its lead candidate, onapristone extended release (ONA-XR).
Centrexion Therapeutics announced a successful raise of $40.5 million through convertible security investments from Lilly and Exome Asset Management, along with expanded lending from Solar Capital Partners. This capital will bolster Centrexion's pipeline of four clinical-stage drug candidates targeting chronic pain, including therapies in Phase 3 and Phase 2a trials. With over $75 million in cash post-fundraise, the company plans further in-licensing of promising mid-stage assets. The ongoing collaboration with Lilly further validates Centrexion's strategy in the pain management sector.